论文部分内容阅读
目的观察尤瑞克林联合依达拉奉治疗急性脑梗死临床疗效。方法 102例急性脑梗死患者,按照随机双盲法分成观察组和对照组,各51例。观察组采用尤瑞克林联合依达拉奉治疗,对照组给予单纯依达拉奉治疗,比较两组临床疗效。结果观察组总有效率为96.08%,对照组为74.51%,比较差异具有统计学意义(P<0.05);治疗后,观察组美国国立卫生研究院卒中量表(NIHSS)评分改善效果优于对照组和治疗前(P<0.05)。结论急性脑梗死采取尤瑞克林联合依达拉奉治疗,治疗效果较佳,且能改善患者的神经功能,值得临床广泛应用和推广。
Objective To observe the clinical effect of uracil combined edaravone in the treatment of acute cerebral infarction. Methods A total of 102 patients with acute cerebral infarction were divided into observation group and control group according to a randomized double-blind method, with 51 cases in each. The observation group was treated with uracil combined with edaravone and the control group with edaravone alone. The clinical efficacy was compared between the two groups. Results The total effective rate was 96.08% in the observation group and 74.51% in the control group, with statistical significance (P <0.05). After the treatment, the NIHSS score in the observation group was better than that of the control group Group and before treatment (P <0.05). Conclusion The treatment of acute cerebral infarction combined with edaravir combined with edaravone has good therapeutic effect and can improve the neurological function of patients. It is worthy of wide application and promotion in clinic.